Alphanate 1000 I.U. ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
288	Autoimmune acquired coagulation factor deficiency	1

288. Autoimmune acquired coagulation factor deficiency

---

Clinical trials : 205 /  Drugs : 238 - (DrugBank : 31) / Drug target genes : 18 - Drug target pathways : 26

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2006-001383-23-GB (EUCTR)	19/04/2012	13/01/2010	Efficacy, safety and pharmaco-economic assessment of secondary long term prophylaxis with highly purified, standardized, doubly virus inactivated FVIII/VWF concentrates in patients with severe, inherited VWD and frequent bleedings.	Efficacy, safety and pharmaco-economic assessment of secondary long term prophylaxis with highly purified, standardized, doubly virus inactivated FVIII/VWF concentrates in patients with severe, inherited VWD and frequent bleedings.	Severe, inherited von Willebrand disease (VWD) and frequent bleedings MedDRA version: 14.1;Level: PT;Classification code 10047715;Term: Von Willebrand's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]	Trade Name: Alphanate Product Name: Alphanate 1000 I.U. Other descriptive name: HUMAN COAGULATION FACTOR VIII Other descriptive name: HUMAN VON WILLEBRAND FACTOR Trade Name: Alphanate Product Name: Alphanate 1500 I.U. Other descriptive name: HUMAN COAGULATION FACTOR VIII Other descriptive name: HUMAN VON WILLEBRAND FACTOR	Prof Flora Peyvandi, MD	NULL	Not Recruiting			Female: yes Male: yes	24	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	Spain;Germany;Italy;United Kingdom